Skip to main content

GSK plc 6-K, filed Oct 26, 2026

GSK plc (GSK)

6-K 2026-10-26 For: 2026-10-26
View Original
Added on October 26, 2026

About this 6-K

GSK plc filed this 6-K on October 26, 2026.

GSK reported positive phase Ib BEHOLD-1 results for Mo-Rez in platinum-resistant ovarian cancer: 62% confirmed objective response rate, 12.2-month median duration of response and 11.1-month median progression-free survival; five pivotal phase III studies are underway. AI summary